Autopsy and clinical findings in @entity3052 and chronic @entity66 --an evaluation of 104 XXXX .

@entity1 @entity295 @entity1148 @entity66 @entity548 @entity55 @entity2617 @entity75 @entity3052 @entity1151 @entity281 @entity693 @entity4018 @entity509 @entity32942 @entity204 @entity15 @entity1210
In @entity3052 ( @entity3052 -46 @entity1 ) and various entities of chronic @entity66 ( @entity32942 -58 @entity1 ) an evaluation and comparison of clinical and postmortem findings has been performed. This study included also aspirates and core biopsies of the bone marrow which were initially taken on admission of those @entity1 . Classification of @entity32942 was done following the concept of Georgii et al. (1984) into CGL -24-, CMGM-6-, E- @entity15 -13- and @entity15 /OMS-15 cases. There was a significant increase in blastic crisis in CGL compared with the other entities and in the latter a prolongation of the total course of disease due to a long period between symptoms--clinical diagnosis. As revealed by the autopsies causes of @entity204 were @entity281 ( @entity55 , @entity295 -50%) and lethal @entity548 (gastrointestinal and cerebral--about 30%) in both @entity3052 and CMGM @entity1 . Rare causes comprised fatal @entity1151 due to a peripheral @entity1148 in @entity32942 , @entity2617 of the myocard in @entity3052 . In addition to the well known giant enlargement of the spleen in @entity15 /OMS, the relatively high frequency of a @entity693 (meningeosis leukemica) in @entity3052 (about 35%) and during an acute transformation in @entity32942 (up to 30%) was conspicuous. The examination of the bone marrow at various sites became feasible during the postmortem procedure and thus provided the opportunity to investigate the development and extent of a @entity4018 evolving in @entity32942 . In contrast to the a- or @entity509 and regeneration of the @entity1210 following chemotherapy, the evolution of @entity75 showed a very uniform pattern throughout the skeleton and obviously no reversal of a manifest @entity15 /OMS after cytotoxic treatment.
